Subtopic Deep Dive

← Protein Kinase Regulation and GTPase Signaling

MAP Kinase Pathways Cancer
Research Guide

What is MAP Kinase Pathways Cancer?

MAP kinase pathways in cancer encompass ERK, JNK, and p38 MAPK cascades that drive cell proliferation, stress responses, and oncogenesis through dysregulated signaling.

These pathways involve sequential activation of MAPKKK, MAPKK, and MAPK modules responding to growth factors, cytokines, and stress. ERK promotes proliferation in BRAF-mutant cancers like melanoma, while JNK and p38 mediate apoptosis and inflammation. Over 10,000 papers document their roles, with key inhibitors like PD 098059 targeting MAPKK1 (Alessi et al., 1995, 3421 citations).

Curated Papers

Key Challenges

Why It Matters

MAPK pathways guide precision medicine in BRAF-mutant melanoma, where ERK inhibitors face resistance via feedback reactivation (Roskoski, 2012). JNK activation by UV and oncoproteins potentiates c-Jun in tumors (Hibi et al., 1993). p38 MAPK responds to pro-inflammatory cytokines, influencing cancer inflammation (Raingeaud et al., 1995). Rho GTPases crosstalk with MAPKs amplifies oncogenic signaling (Van Aelst and D’Souza-Schorey, 1997). Inhibitor selectivity profiling enables targeted therapies (Bain et al., 2007).

Key Research Challenges

Inhibitor Selectivity

Many kinase inhibitors lack specificity across 70-80 kinases, causing off-target effects in MAPK pathways (Bain et al., 2007). PD 098059 specifically blocks MAPKK1 activation but requires validation in vivo (Alessi et al., 1995). Profiling 65 compounds reveals cross-reactivity challenges in cancer therapy.

Feedback Resistance

ERK inhibition triggers feedback loops reactivating pathways in BRAF-mutant cancers (Roskoski, 2012). JNK and p38 dual phosphorylation resists stress-induced apoptosis (Raingeaud et al., 1995). Crosstalk with Rho GTPases complicates intervention (Van Aelst and D’Souza-Schorey, 1997).

Pathway Crosstalk

MAPK cascades intersect with non-Smad TGF-β and death receptor signals, altering oncogenesis (Zhang, 2008; Irmler et al., 1997). Regulation by dual Tyr/Thr phosphorylation varies by stimulus (Cobb and Goldsmith, 1995). Quantifying network interactions remains difficult.

Essential Papers

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo

Dario R. Alessi, Ana Cuenda, Philip Cohen et al. · 1995 · Journal of Biological Chemistry · 3.4K citations

PD 098059 has been shown previously to inhibit the dephosphorylated form of mitogen-activated protein kinase kinase-1 (MAPKK1) and a mutant MAPKK1(S217E,S221E), which has low levels of constitutive...

Inhibition of death receptor signals by cellular FLIP

Martin Irmler, Margot Thome, Michael Hahne et al. · 1997 · Nature · 2.6K citations

The selectivity of protein kinase inhibitors: a further update

Jenny Bain, Lorna Plater, Matt Elliott et al. · 2007 · Biochemical Journal · 2.5K citations

The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70–80 protein kinases. On the basis of this information, the...

Rho GTPases and signaling networks

Linda Van Aelst, Crislyn D’Souza‐Schorey · 1997 · Genes & Development · 2.4K citations

The Rho GTPases form a subgroup of the Ras superfamily of 20- to 30-kD GTP-binding proteins that have been shown to regulate a wide spectrum of cellular functions. These proteins are ubiquitously e...

Pro-inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine

Joël Raingeaud, Shashi Kumar Gupta, Jeffrey S. Rogers et al. · 1995 · Journal of Biological Chemistry · 2.2K citations

Protein kinases activated by dual phosphorylation on Tyr and Thr (MAP kinases) can be grouped into two major classes: ERK and JNK. The ERK group regulates multiple targets in response to growth fac...

Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.

Masahiko Hibi, Anning Lin, Tod Smeal et al. · 1993 · Genes & Development · 1.9K citations

The activity of c-Jun is regulated by phosphorylation. Various stimuli including transforming oncogenes and UV light, induce phosphorylation of serines 63 and 73 in the amino-terminal activation do...

How MAP Kinases Are Regulated

Melanie H. Cobb, Elizabeth J. Goldsmith · 1995 · Journal of Biological Chemistry · 1.7K citations

The closely related MAP kinases,1(1) extracellular signal-regulated protein kinases 1 and 2 (ERK1 and ERK2), are ubiquitous components of signal transduction pathways. ERK1 and ERK2 are activated b...

Reading Guide

Foundational Papers

Start with Alessi et al. (1995) for MAPKK1 inhibition by PD 098059 (3421 citations), Raingeaud et al. (1995) for p38/JNK activation (2227 citations), and Cobb and Goldsmith (1995) for MAPK regulation overview (1729 citations).

Recent Advances

Roskoski (2012) details ERK1/2 structure and cancer roles (1616 citations); Bain et al. (2007) updates inhibitor selectivity (2489 citations).

Core Methods

Dual Tyr/Thr phosphorylation assays (Raingeaud et al., 1995); kinase inhibitor profiling panels (Bain et al., 2007); c-Jun potentiation binding (Hibi et al., 1993).

How PapersFlow Helps You Research MAP Kinase Pathways Cancer

Discover & Search

Research Agent uses searchPapers and exaSearch to find 250M+ OpenAlex papers on 'MAPK ERK cancer resistance', then citationGraph on Alessi et al. (1995) reveals PD 098059 inhibitor citations. findSimilarPapers expands to JNK/p38 cascades from Raingeaud et al. (1995).

Analyze & Verify

Analysis Agent applies readPaperContent to extract phosphorylation mechanisms from Cobb and Goldsmith (1995), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis on kinase selectivity data from Bain et al. (2007) for statistical profiling (GRADE: A for inhibitor specificity).

Synthesize & Write

Synthesis Agent detects gaps in MAPK-Rho crosstalk (Van Aelst and D’Souza-Schorey, 1997), flags contradictions in inhibitor effects, and uses latexEditText with latexSyncCitations for pathway diagrams via exportMermaid; Writing Agent compiles LaTeX reports with latexCompile.

Use Cases

"Plot citation trends and inhibitor selectivity for MAPK papers 1995-2012"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on citation data from Alessi 1995, Bain 2007) → matplotlib plot of selectivity scores and trends.

"Write LaTeX review on ERK inhibitor resistance in melanoma"

Research Agent → citationGraph (Roskoski 2012) → Synthesis → gap detection → Writing Agent → latexEditText + latexSyncCitations (10 papers) + latexCompile → formatted PDF with ERK cascade figure.

"Find GitHub repos analyzing JNK activation data from Hibi 1993"

Research Agent → paperExtractUrls (Hibi et al. 1993) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified code for c-Jun phosphorylation simulation.

Automated Workflows

Deep Research workflow scans 50+ MAPK cancer papers via searchPapers → citationGraph → structured report with GRADE scores on inhibitor efficacy (Alessi 1995). DeepScan applies 7-step CoVe to verify p38 activation claims (Raingeaud 1995), checkpointing crosstalk analysis. Theorizer generates hypotheses on JNK-ERK feedback from Hibi (1993) and Roskoski (2012).

Try Doxa for MAP Kinase Pathways Cancer Research

Frequently Asked Questions

What defines MAP kinase pathways in cancer?

ERK, JNK, and p38 cascades drive proliferation and stress responses via dual Tyr/Thr phosphorylation, dysregulated in oncogenesis (Cobb and Goldsmith, 1995).

What are key methods for studying these pathways?

Inhibitors like PD 098059 block MAPKK1 (Alessi et al., 1995); selectivity profiling tests 65 compounds on 70 kinases (Bain et al., 2007).

What are seminal papers?

Alessi et al. (1995, 3421 citations) on PD 098059; Raingeaud et al. (1995, 2227 citations) on p38 activation; Hibi et al. (1993, 1894 citations) on JNK-c-Jun.

What open problems exist?

Resistance to ERK inhibitors via feedback (Roskoski, 2012); MAPK-Rho crosstalk quantification (Van Aelst and D’Souza-Schorey, 1997); non-Smad pathway integration (Zhang, 2008).